ArticleFrontiers in epidemiology2026
Detecting comorbidity patterns in rare disease patients with machine learning.
Article in Frontiers in epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Whilst individually rare, affecting only a small percentage of the population, rare diseases as a whole impact around 6% of the global population (with this number likely an underestimate). Rare diseases are often complex, with specific challenges in diagnosis, management, and treatment due to limited knowledge and research. Rare disease patients have been shown to have more comorbidities compared to those without a rare disease diagnosis. Studying comorbidities in patients with rare diseases is particularly important as these patients may exhibit unique patterns of multiple diseases which are not well understood. Understanding these comorbidity patterns can lead to insights into the etiology and progression of rare diseases, potentially identifying new therapeutic targets and improving clinical management strategies. Additionally, studying comorbidities can help in predicting complications, improving the quality of life of patients, and offering a more comprehensive approach to health care for those affected by rare diseases. Methods: A machine learning based method known as hierarchical clustering was applied to diagnosis data from the UK Biobank to study comorbidity patterns in patients with rare diseases. The results were then compared with patterns detected for the general population. Results: Twelve clusters were identified for the rare disease group, and 14 for the no rare disease group. Discussion: Unique comorbidity patterns were observed for individuals with and without a rare disease diagnosis, highlighting potential priorities for intervention to improve both disease management and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.